Cure Alzheimer’s Fund Reaches $100 Million Milestone

Cure Alzheimer’s Fund Reaches $100 Million Milestone
0
(0)

In awarding more than $100 million to support scientific efforts to prevent, slow or reverse Alzheimer’s disease, the nonprofit Cure Alzheimer’s Fund has reached a significant milestone.

Since its founding, the 15-year-old organization has backed some 425 novel projects conducted by 170 investigators worldwide. Those projects have resulted in the publication of more than 525 peer-reviewed research papers, and in breakthroughs that could lead to development of innovative Alzheimer’s treatments.

Of late, the organization said, there has been major interest in studies involving the permeability of the blood-brain barrier — the semipermeable membrane that protects the brain against the external environment, and is a major barrier for the efficient delivery of certain therapeutics that need to reach the brain and central nervous system.

A new Cure Alzheimer’s-supported initiative, the Berg Brain Entry and Exit Consortium, is fostering multi-institutional partnerships focused on the relationship between cerebrovascular function and neuroimmune activation and resolution, sparking prospective new ways to develop and deliver therapies that can cross the blood-brain barrier.

The organization also cited as one of Cure Alzheimer’s top breakthroughs the Alzheimer’s Genome Project, the first large-scale, family-based study of the human genome specific to the disease. The Massachusetts General Hospital-led study was the first to report new Alzheimer’s genes with statistical significance, with more than 100 gene candidates being identified in the project’s first phase. Launched in 2005, the project screened some 400 Alzheimer’s families for genes that might increase risk for, or offer protection against, the disease, and provided the foundation for other major genetic studies.

Another Cure Alzheimer’s-supported breakthrough was last year’s Alzheimer’s in a Dish, an advanced model of the disease that gives researchers an important tool for developing potential new therapies. The model is basically a culture of human brain cells that can display the two most salient hallmarks of Alzheimer’s disease: plaques and tangle. These cells organize into three-dimensional structures and display signs of neuroinflammation, a condition that leads to brain cell death. The culture also employs glial cells, which surround and insulate brain nerve cells.

Go here to learn more about research by Cure Alzheimer’s Fund scientists and projects. Discovery topics include general anesthetics, amyloid, air pollution, the gut microbiome, and exercise.

“For 15 years, our board of directors of Cure Alzheimer’s Fund has remained committed to allowing and encouraging the researchers we fund to follow the science and explore high risk/high reward hypotheses,” Tim Armour, the organization’s president and CEO, said in a press release. “Today, there is great momentum and new discoveries. We are honored to have been the recipients of the generosity of more than 45,000 donors who have made this research possible.”

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 282
Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • children's storybook about Alzheimer's
  • UsAgainstAlzheimer’s
  • HFC CareCon
  • Alzheimer's and Blacks in US

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?